Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic dermatitis, where the candidate successfully reduced the size and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results